Payment overview · 2025
General Payments
$243.55
15 reported records · 5 companies
Healthcare provider profile · identity verified
Christopher M Labuda, DO
Allopathic & Osteopathic Physicians|Internal Medicine · UNIONTOWN, PA · NPI 1972095396
Verified facts
What the public records show
CMS Open Payments records show Christopher M Labuda, DO received $243.55 in general payments during 2025 across 15 reported records.
PFIZER INC. accounted for 59.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $145.50 | 59.7% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.91 | 19.3% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.35 | 7.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.28 | 7.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.51 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $243.55 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $126.65 | 8 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $83.10 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $48.82 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 234 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
234 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
234 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 550 | 134 |
| Lisinopril | Lisinopril | 437 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 355 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 318 | 77 |
| Gabapentin | Gabapentin | 293 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 265 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 246 | 59 |
| Eliquis | Apixaban | 234 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 217 | 52 |
| Metformin Hcl | Metformin Hcl | 207 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 44 |
| Furosemide | Furosemide | 202 | 57 |
| Potassium Chloride | Potassium Chloride | 188 | 34 |
| Sertraline Hcl | Sertraline Hcl | 174 | 35 |
| Losartan Potassium | Losartan Potassium | 173 | 44 |
| Omeprazole | Omeprazole | 142 | 44 |
| Ozempic | Semaglutide | 142 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 35 |
| Simvastatin | Simvastatin | 119 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 36 |
| Trazodone Hcl | Trazodone Hcl | 113 | 27 |
| Meloxicam | Meloxicam | 110 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 28 |
| Jardiance | Empagliflozin | 94 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 42 |
| Famotidine | Famotidine | 92 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 86 | 17 |
| Donepezil Hcl | Donepezil Hcl | 85 | 17 |
| Irbesartan | Irbesartan | 84 | 18 |
| Buspirone Hcl | Buspirone Hcl | 83 | 26 |
| Carvedilol | Carvedilol | 81 | 25 |
| Mounjaro | Tirzepatide | 81 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 23 |
| Xarelto | Rivaroxaban | 69 | 11 |
| Azithromycin | Azithromycin | 67 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | suppressed |
| Pregabalin | Pregabalin | 66 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 15 |
| Risperidone | Risperidone | 58 | suppressed |
| Alprazolam | Alprazolam | 55 | 15 |
| Ezetimibe | Ezetimibe | 55 | 14 |
| Ibuprofen | Ibuprofen | 54 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 53 | 14 |
| Methylprednisolone | Methylprednisolone | 53 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 12 |
| Prednisone | Prednisone | 50 | 27 |
| Allopurinol | Allopurinol | 49 | 12 |
| Mirtazapine | Mirtazapine | 49 | suppressed |
| Atenolol | Atenolol | 48 | 13 |
| Glimepiride | Glimepiride | 48 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 12 |
| Propranolol Hcl | Propranolol Hcl | 45 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 45 | 34 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | suppressed |
| Fluconazole | Fluconazole | 42 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 16 |
| Finasteride | Finasteride | 41 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | 11 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 33 | 33 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | 11 |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 29 | 11 |
| Tramadol Hcl | Tramadol Hcl | 29 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 27 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 13 |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Nystatin | Nystatin | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 15 |
| Glipizide | Glipizide | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 13 |
| Tradjenta | Linagliptin | 16 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | 11 |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $243.55 · 15 records | PFIZER INC. | ELIQUIS, NURTEC ODT, Veozah, ZAVZPRET, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error